 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Phase classification: Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - Apr 16, 2024
P1, N=27, Active, not recruiting, Sponsor: Washington University School of Medicine
Phase classification: P1b --> P1
- | mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - Feb 13, 2023
P1b, N=27, Active, not recruiting, Sponsor: Washington University School of Medicine
Phase classification: P1b --> P1 Recruiting --> Active, not recruiting | N=56 --> 27 | Trial completion date: Jan 2029 --> Aug 2028 | Trial primary completion date: Jun 2024 --> Apr 2022
- | mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Trial completion date, Trial primary completion date: Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - Jan 31, 2023
P1b, N=56, Recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting | N=56 --> 27 | Trial completion date: Jan 2029 --> Aug 2028 | Trial primary completion date: Jun 2024 --> Apr 2022 Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jun 2023 --> Jun 2024
- | mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Trial completion date, Trial primary completion date: Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - Jan 27, 2022
P1b, N=56, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jun 2023 --> Jun 2024 Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jun 2022 --> Jun 2023
- | mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Trial completion date, Trial primary completion date: Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - Dec 17, 2018
P1b, N=46, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jun 2022 --> Jun 2023 Trial completion date: Oct 2024 --> Jan 2027 | Trial primary completion date: Feb 2019 --> Jun 2022
- mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Enrollment change, Trial primary completion date: Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - Feb 3, 2016
P1b, N=60, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Oct 2024 --> Jan 2027 | Trial primary completion date: Feb 2019 --> Jun 2022 N=12 --> 60 | Trial primary completion date: Feb 2017 --> Feb 2019
- mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Enrollment open: Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - Jan 8, 2015
P1b, N=12, Recruiting, Sponsor: Washington University School of Medicine
N=12 --> 60 | Trial primary completion date: Feb 2017 --> Feb 2019 Not yet recruiting --> Recruiting
- mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Trial completion, Metastases: Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer (clinicaltrials.gov) - Jan 5, 2015
P1, N=15, Completed, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- mammaglobin-A DNA vaccine / Washington University School of Medicine in St. Louis
Enrollment closed, Trial primary completion date, Metastases: Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer (clinicaltrials.gov) - Jul 25, 2014
P1, N=15, Active, not recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Mar 2014